144 results on '"Rosenkrans, Zachary T."'
Search Results
2. Supplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
3. FIGURE 1 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
4. FIGURE 5 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
5. Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
6. Supplementary Figure 1 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
7. Data from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
8. Supplementary Figure 5 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
9. FIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
10. FIGURE 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
11. FIGURE 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
12. Supplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
13. Supplementary Figure 6 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
14. Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma
15. Mechanistic Characterization of Cancer Associated Fibroblast Depletion via an Antibody-Drug Conjugate Targeting Fibroblast Activation Protein
16. Multimodal imaging demonstrates enhanced tumor exposure of PEGylated FUD peptide in breast cancer
17. Investigating the In Vivo Biodistribution of Extracellular Vesicles Isolated from Various Human Cell Sources Using Positron Emission Tomography.
18. [ 64 Cu]Cu-PEG-FUD peptide for noninvasive and sensitive detection of murine pulmonary fibrosis
19. Amplification of Cerenkov Luminescence Using Semiconducting Polymers for Cancer Theranostics
20. 64Cu-Labeled Aptamers for Tumor-Targeted Radionuclide Delivery
21. Scavenging of reactive oxygen and nitrogen species with nanomaterials
22. ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab
23. Investigating the in vivo biodistribution of extracellular vesicles isolated from various human cell sources using positron emission tomography
24. [68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity.
25. Ultrasmall Porous Silica Nanoparticles with Enhanced Pharmacokinetics for Cancer Theranostics
26. CD38‐Targeted Theranostics of Lymphoma with 89 Zr/ 177 Lu‐Labeled Daratumumab
27. PET imaging of macrophages in cardiovascular diseases
28. HER2-targeted multimodal imaging of anaplastic thyroid cancer
29. Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab′)2 Fragments of Obinutuzumab in Lymphoma
30. Nanomedicines for Renal Management: From Imaging to Treatment
31. Internally Responsive Nanomaterials for Activatable Multimodal Imaging of Cancer
32. Selenium‐Doped Carbon Quantum Dots Act as Broad‐Spectrum Antioxidants for Acute Kidney Injury Management
33. ImmunoPET: Concept, Design, and Applications
34. 86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics
35. Total-Body PET Imaging for up to 30 Days After Injection of 89Zr-Labeled Antibodies
36. A “Missile‐Detonation” Strategy to Precisely Supply and Efficiently Amplify Cerenkov Radiation Energy for Cancer Theranostics
37. CD38‐Targeted Theranostics of Lymphoma with 89Zr/177Lu‐Labeled Daratumumab.
38. Smart H 2 S‐Triggered/Therapeutic System (SHTS)‐Based Nanomedicine
39. Intrathecal Administration of Nanoclusters for Protecting Neurons against Oxidative Stress in Cerebral Ischemia/Reperfusion Injury
40. A Melanin‐Based Natural Antioxidant Defense Nanosystem for Theranostic Application in Acute Kidney Injury
41. Radionuclide‐Activated Nanomaterials and Their Biomedical Applications
42. Aptamer-Conjugated Framework Nucleic Acids for the Repair of Cerebral Ischemia-Reperfusion Injury
43. Ceria Nanoparticles Meet Hepatic Ischemia‐Reperfusion Injury: The Perfect Imperfection
44. Radionuklidaktivierte Nanomaterialien und ihre biomedizinische Anwendung
45. Nanozyme: new horizons for responsive biomedical applications
46. Efficient Tumor and Mitochondria Uptake of 177Lu-Porphyrin-PEG Nanocomplexes for Multimodal Imaging Guided Combination Therapy
47. Exploiting Nanomaterial-Mediated Autophagy for Cancer Therapy
48. Internally Responsive Nanomaterials for Activatable Multimodal Imaging of Cancer.
49. Noninvasive evaluation of CD20 expression using 64Cu-labeled F(ab')2 fragments of obinutuzumab in lymphoma.
50. Noninvasive evaluation of CD20 expression using 64Cu-labeled F(ab')2 fragments of obinutuzumab in lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.